Our clinical pages are read by practising clinicians who have no stake in what this site recommends. This page names them, and says exactly what each of them signed off on.
How the review works
Reviewers are independent. They are not employed by PsyAccess, they are not listed providers, and they have no commercial interest in anyone in our directory. They are asked to do one thing: check our clinical statements against evidence-based practice and current research, and flag anything that overstates a result, omits a material risk, or misdescribes a regulatory status.
Comments come back as a structured list — quoted fragment, correction, and whether the correction is critical or optional. We apply them, the reviewer confirms the corrected text, and only then does a name go on the page. Each reviewed page carries the review date; where the evidence moves, the page is re-reviewed rather than quietly edited.
Two levels of review are published, and we distinguish them deliberately:
Page level — “Medically reviewed by …” at the top of a guide means the reviewer read the whole guide.
Section level — a note next to a specific section means the review covers that section only. Our country access guides work this way: the shared clinical sections (what treatment involves, and risks) are reviewed, while the administrative and regulatory parts of the page are editorially fact-checked against primary sources rather than clinically reviewed.
Medical review does not make a page medical advice, and it is not an endorsement of any provider in the directory. See our editorial policy for how guides are produced before they reach a reviewer.
Reviewers
Dr. Amy Reichelt, PhD
Neuroscientist, chartered psychologist and psychotherapist
PhD·Canada
Dr. Reichelt is a neuroscientist, Chartered Psychologist (BPS) and registered psychotherapist with more than fifteen years spent turning brain science into clinically grounded mental-health care. She earned her PhD in behavioural neuroscience at Cardiff University and has published over seventy peer-reviewed scientific papers.
She has completed advanced training in trauma therapy and psychedelic-assisted therapy, and her clinical and research interests sit exactly where this site’s questions do: how altered states and neuroplasticity are used therapeutically, what the evidence actually supports, and how screening and integration fit around a dosing session. In her Toronto practice, Cultivae, she works with anxiety, trauma and stress-related conditions using ACT, CBT and somatic, trauma-informed approaches.
Alongside clinical work she advises life-science and mental-health companies on clinical-trial strategy, translational neuroscience and psychedelic medicine development. She also sits on the review board of our sister publication, States of Mind.
Reviewed for PsyAccess
Psilocybin therapy: what the evidence shows
MDMA-assisted therapy: what the evidence shows
The clinical sections of every country access guide — what treatment involves, and risks
We are adding reviewers, in particular psychiatrists practising in Europe. If you are a licensed clinician working in psychiatry, anaesthesia and critical care, addiction medicine or psychology, and you would consider reviewing this material, write to hello@psyaccess.health. We publish the reviewer's name, credentials and review date, and we ask for consent to do so before anything is published.